Observational study of the extent of lymph node metastasis among patients who underwent pancreatoduodenectomy for non-ampullary duodenal cancer using the National Clinical Database in Japan. This is ...
A phase II study of peri-operative NovoTTF-200T(P) in combination with gemcitabine and nab-paclitaxel for resectable pancreatic adenocarcinoma: Big Ten Cancer Research Consortium (BTCRC-GI21-500).
THE proportion of people diagnosed with lung cancer who’ve never smoked is increasing, the World Health Organization (WHO) ...
In this small series it seems that fistulas may ... These figures compare favorably with those reported in uncomplicated carcinoma of the large bowel. Of the 28 patients surviving for five years ...
Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...
Lipogenic and Metabolic Subtypes Define Survival Outcome in Pancreatic Adenocarcinoma Patients In-Person Session Name: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary ...
Emily King of Mobile, Alabama, was diagnosed with colon cancer five years ago at the age of 27. She had experienced some diarrhea, abdominal pain and anemia, but having cancer had never entered ...
Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory ...
The specific SIRs for non Hodgkin lymphoma was 4.7; 95% CI = 2.9-7.3 p < 0.001, for the small bowel carcinoma 25; 95% CI = 8.5-51.4 p < 0.001, for non Hodgkin lymphoma 10; 95% CI = 2.7-25 p = 0.01 ...
The HUMANOID Center at UC San Diego is pioneering organoid research aimed at improving the reliability and reproducibility of ...
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including ...